Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sinocelltech Files for Hong Kong Secondary Listing to Expand Global Capital Access and Therapeutic Portfolio

Fineline Cube May 25, 2026
Company Deals Medical Device

Lifetech Scientific to Acquire Starway Medical Technology in $276 Million Deal to Expand Structural Heart Portfolio

Fineline Cube May 25, 2026
Company Deals

Johnson & Johnson MedTech Partners with Beijing Shijitan Hospital to Establish China’s First Split-Type Surgical Robot Training Base

Fineline Cube May 25, 2026
Company Deals

Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions

Fineline Cube May 22, 2026
Company Deals

Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform

Fineline Cube May 22, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Cloudbreak Pharma Submits FDA IND for CBT-358, Novel SFA+ Technology-Based Dry Eye Treatment

Fineline Cube May 25, 2026
Company Drug

Henlius Biotech’s PD-1 Inhibitor Hetronifly Receives CHMP Recommendation for Squamous NSCLC in EU

Fineline Cube May 25, 2026
Policy / Regulatory

China’s National Adverse Drug Reaction Report for 2023 Highlights Stability in Reporting Trends

Fineline Cube Mar 27, 2024

The National Center for ADR Monitoring has released its “National Adverse Drug Reaction Monitoring Annual...

Company

Lee’s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs

Fineline Cube Mar 27, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading pharmaceutical company based in China, has released...

Company

Hansoh Pharmaceutical Group Reports 7.7% YOY Revenue Growth and Expands R&D Spending

Fineline Cube Mar 27, 2024

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced its financial results for 2023, reporting...

Company Deals

Shanghai Pharmaceuticals, SHC, and CEMCS CAS Renew Partnership to Incubate Pharmaceutical Innovations

Fineline Cube Mar 27, 2024

Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, SHA: 601607; HKG: 2607), a leading pharmaceutical company in...

Company Policy / Regulatory

Kobayashi Pharmaceutical Recalls Red Yeast Rice Pills in China Amid Health Concerns

Fineline Cube Mar 26, 2024

Japan-based Kobayashi Pharmaceutical has reportedly initiated a product recall in the Chinese market for its...

Company Policy / Regulatory

Surprise Resignation: Congressman Gallagher Steps Down as Biosecure Act Faces Uncertainty

Fineline Cube Mar 26, 2024

U.S. Congressman Mike Gallagher, the key proponent behind the recently introduced Biosecure Act aimed at...

Company Deals

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Deal Amid Biotech Pressures

Fineline Cube Mar 26, 2024

U.S.-based biotech Nuvation Bio Inc. (NYSE: NUVB) has announced a definitive agreement to acquire China-based...

Company Drug

FDA Grants Full Approval to AbbVie’s Elahere for Advanced Ovarian Cancer Treatment

Fineline Cube Mar 26, 2024

This week, the U.S. Food and Drug Administration (FDA) granted full approval to AbbVie’s (NYSE:...

Company Deals Hospital

Fosun Health and Adventist Medical Center Partner to Enhance GBA Medical Services

Fineline Cube Mar 26, 2024

China-based Fosun Health Consumption Industry Group has entered into a strategic partnership with Hong Kong’s...

Company Deals Drug

Biocytogen and ABL Bio Forge Partnership to Advance Bispecific ADC Development

Fineline Cube Mar 26, 2024

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with South...

Company Deals

HitGen Secures Strategic Partnerships to Enhance Drug Discovery for Startups

Fineline Cube Mar 26, 2024

China-based HitGen Inc. (SHA: 688222) has announced strategic partnerships with LabCentral, a prominent life science...

Company Drug

CanSino Biologics Launches Phase III Study for Menhycia Vaccine in Indonesia

Fineline Cube Mar 26, 2024

China-based CanSino Biologics (HKG: 6185) has announced the launch of a Phase III clinical study...

Company Deals

Novo Nordisk Acquires Cardior for €1.025 Billion to Strengthen Cardiovascular Portfolio

Fineline Cube Mar 26, 2024

Denmark-based Novo Nordisk (CPH: NOVO-B) has announced a significant agreement to acquire Germany’s Cardior, a...

Company

Kelun-Biotech Reports Robust 91.6% Revenue Growth Amid Strategic Licensing Efforts

Fineline Cube Mar 26, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) reported its 2023 financial results, revealing revenues of...

Company Drug

Guangdong Zhongsheng Reports Positive Phase I Results for Innovative Weight Loss Drug RAY1225

Fineline Cube Mar 26, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based biopharmaceutical company, has announced promising top-line...

Company Medical Device

Zylox-Tonbridge Secures NMPA Approval for Advanced Flow Diverter Targeting Intracranial Aneurysms

Fineline Cube Mar 26, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...

Company Deals

Novo Nordisk Expands Benzalkonium Chloride Distribution with Actylis Across Europe

Fineline Cube Mar 26, 2024

Denmark’s Novo Nordisk (CPH: NOVO-B), through its Pharmatech division, announced a partnership this week with...

Company

WuXi XDC Reports 114.4% YOY Revenue Growth in 2023, Driven by ADC CRDMO Business

Fineline Cube Mar 26, 2024

WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

Jiangsu Hengrui’s Generic Version of Tepadina Approved for Transplantation Conditioning in China

Fineline Cube Mar 26, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

MSD’s Phase III Trial of Keytruda Plus Lynparza Misses Primary Endpoints in NSCLC

Fineline Cube Mar 25, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an unfavorable outcome for a Phase...

Posts pagination

1 … 389 390 391 … 671

Recent updates

  • Sinocelltech Files for Hong Kong Secondary Listing to Expand Global Capital Access and Therapeutic Portfolio
  • Lifetech Scientific to Acquire Starway Medical Technology in $276 Million Deal to Expand Structural Heart Portfolio
  • Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development
  • Johnson & Johnson MedTech Partners with Beijing Shijitan Hospital to Establish China’s First Split-Type Surgical Robot Training Base
  • Cloudbreak Pharma Submits FDA IND for CBT-358, Novel SFA+ Technology-Based Dry Eye Treatment
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Sinocelltech Files for Hong Kong Secondary Listing to Expand Global Capital Access and Therapeutic Portfolio

Company Deals Medical Device

Lifetech Scientific to Acquire Starway Medical Technology in $276 Million Deal to Expand Structural Heart Portfolio

Company R&D

Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development

Company Deals

Johnson & Johnson MedTech Partners with Beijing Shijitan Hospital to Establish China’s First Split-Type Surgical Robot Training Base

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.